Barbara De Moerloose
About
In The Last Decade
Barbara De Moerloose
117 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 94
- Molecular Biology 677
- Hematology 644
- Public Health, Environmental and Occupational Health 510
- Oncology 454
- Pediatrics, Perinatology and Child Health 267
Countries citing papers authored by Barbara De Moerloose
This map shows the geographic impact of Barbara De Moerloose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara De Moerloose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara De Moerloose more than expected).
Fields of papers citing papers by Barbara De Moerloose
This network shows the impact of papers produced by Barbara De Moerloose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara De Moerloose. The network helps show where Barbara De Moerloose may publish in the future.
Co-authorship network of co-authors of Barbara De Moerloose
This figure shows the co-authorship network connecting the top 25 collaborators of Barbara De Moerloose. A scholar is included among the top collaborators of Barbara De Moerloose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara De Moerloose. Barbara De Moerloose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 16 | |
| 3 | 1 | |
| 4 | 3 | |
| 5 | 9 | |
| 6 | 82 | |
| 7 | 13 | |
| 8 | 4 | |
| 9 | 39 | |
| 10 | 10 | |
| 11 | The ION-Ghent guidelines for the management of immune related adverse events (irAE's) | 1 |
| 12 | 6 | |
| 13 | PEG-asparaginase in treatment of childhood acute lymphoblastic leukemia | 0 |
| 14 | Musculoskeletal manifestations in children with acute lymphoblastic leukaemia | 2 |
| 15 | Treatment of refractory T-lymphoblastic leukaemia and lymphoma with nelarabine | 1 |
| 16 | Therapeutic efficacy and safety of transfusion of pathogen-inactivated platelets tot pediatric patients | 4 |
| 17 | Imaging with Technetium-99m sestamibi does not predict drug resistance or outcome in childhood neuroblastoma | 0 |
| 18 | 99mTc-MIBI imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein | 1 |
| 19 | Immunocytochemical and flow cytometric analysis of P-glycoprotein in childhood ALL | 0 |
| 20 | Expression of the multidrug transporter, P-glycoprotein, in childhood leukemia: a prospective clinical study | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.